SEND SMS
SEND EMAIL

Anti-Diabetics

Prominent & Leading Manufacturer from Delhi, we offer desmopressin tablets 100mcg, glibenclamide & metformin tablets 251.25mg 500mg, glibenclamide tablets 5mg, gliclazide & metformin hcl tablets 580 mg, gliclazide tablet 80mg and metformin hcl & glimepiride tablets.

Desmopressin Tablets 100mcg

Desmopressin Tablets 100mcg
  • Desmopressin Tablets 100mcg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
BrandFlodesmo
Dose100 mcg
UsageClinic, Hospital, Personal
Packaging Size1 bottle of 15 Tablets
CompositionDesmopressin Tablets

Indications:
  • Indicated for the treatment of vasopressin-sensitive cranial diabetes insipidus or in the treatment of post- hypophysectomy polyuria/polydipsia.

Dosage:
  • Dosage is individual in diabetes insipidus but the total daily sublingual dose normally lies in the range of 120 micrograms to 720 micrograms.
  • A suitable starting dose in adults and children is 60 micrograms three times daily, administered sublingually.
  • This dosage regimen should then be adjusted in accordance with the patient's response.
  • For the majority of patients, the maintenance dose is 60 micrograms to 120 micrograms sublingually three times daily.
Request
Callback
Yes! I am Interested

Glibenclamide & Metformin Tablets 251.25mg 500mg

Glibenclamide & Metformin Tablets 251.25mg 500mg
  • Glibenclamide & Metformin Tablets 251.25mg 500mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength251.25/500 mg
Packaging TypeBox
BrandGenmide-M
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionGlibenclamide & Metformin Tablets

Indications:
  • Glibenclamide is a hypoglycaemic agent indicated in the treatment of non-insulin dependent diabetes in patients who respond inadequately to dietary measures alone.
  • Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
  • In adults, Metformin film-coated tablets may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin.
  • In children from 10 years of age and adolescents, Metformin film-coated tablets may be used as monotherapy or in combination with insulin.
  • A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.

Dosage:

Adults

Monotherapy and combination with other oral antidiabetic agents:
  • The usual starting dose is one tablet 2 or 3 times daily given during or after meals.
  • After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastrointestinal tolerability. The maximum recommended dose of metformin is 3 g daily.
  • If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate metformin at the dose indicated above.

Combination with insulin:
  • Metformin and insulin may be used in combination therapy to achieve better blood glucose control. Metformin is given at the usual starting dose of one tablet 2-3 times daily, while insulin dosage is adjusted on the basis of blood glucose measurements.
  • Elderly: due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary
Request
Callback
Yes! I am Interested

Glibenclamide Tablets 5mg

Glibenclamide Tablets 5mg
  • Glibenclamide Tablets 5mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
Dose/Strength5 mg
BrandGenmide
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionGlibenclamide Tablets

Indications:
  • Glibenclamide is a hypoglycaemic agent indicated in the treatment of non-insulin dependent diabetes in patients who respond inadequately to dietary measures alone.

Dosage:

Treatment of previously untreated diabetes:
  • Stabilisation can be started with one 5mg tablet daily with or immediately after breakfast or the first main meal. If control is satisfactory one tablet is continued as the maintenance dose.
  • If control is unsatisfactory, the dose can be adjusted by increments of 2.5 or 5mg at weekly intervals. The total daily dosage rarely exceeds 15mg and increasing the daily dosage above this does not generally produce any additional affect.
  • The total daily requirement should normally be given as a single dose at breakfast, or with the first main meal. The patients diet and activity should be taken into account.
  • Children: Glibenclamide is not recommenced for use in children.
  • In debilitated patients who may be more liable to hypoglycaemia, treatment should be initiated with one 2.5mg tablet daily.
  • Changeover from other sulphonylureas:
  • The changeover to glibenclamide from other drugs with similar modes of action can be carried out without any break in therapy.
  • Treatment is commenced with the equivalent dose of glibenclamide without exceeding an initial dose of 10mg. If response is inadequate, the dose can be raised in a stepwise fashion to 15mg daily. One 5mg tablet of glibenclamide is approximately equivalent to 1g tolbutamine or glymidine, 250mg chlorpropamide or tolazamide, 500mg acetohexamide, 25mg glibornuride or 5mg glipizide.
  • Changeover from biguanides: The biguanide should be withdrawn and glibenclamide treatment started with one 2.5mg tablet. The dosage should then be adjusted by increments of 2.5mg to achieve control.
Request
Callback
Yes! I am Interested

Gliclazide & Metformin Hcl Tablets 580 mg

Gliclazide & Metformin Hcl Tablets 580 mg
  • Gliclazide & Metformin Hcl Tablets 580 mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength580 mg
Packaging TypeBox
BrandGlizide-M
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionGliclazide & Metformin Hydrochloride Tablets

Indications:
  • Non insulin-dependent diabetes mellitus (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
  • Polycystic Ovaries Syndrome
  • Type 2 Diabetes Mellitus
  • For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM.
  • May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS).
  • the treatment of patients when both linagliptin and metformin is appropriate.
  • For the treatment of NIDDM in conjunction with diet and exercise.

Dosage:
  • The total daily dose may vary from 40 to 320mg taken orally.
Request
Callback
Yes! I am Interested

Gliclazide Tablet 80mg

Gliclazide Tablet 80mg
  • Gliclazide Tablet 80mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose80mg
Packaging Size1x10 tablets
UsageClinical, Hospital, Personal
BrandGlizide-FH
Packaging TypeBox
CompositionGliclazide Tablet

Indications:
  • Non insulin-dependent diabetes mellitus (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

Dosage:
  • The total daily dose may vary from 40 to 320mg taken orally.  Initial dose
  • The total daily dose may vary from 40 to 320 mg taken orally. The dose should be adjusted according to the individual patient's response, commencing with 40-80 mg daily (½- 1 tablet) and increasing until adequate control is achieved. A single dose should not exceed 160 mg (2 tablets). When higher doses are required, Gliclazide 80 mg Tablets should be taken twice daily and according to the main meals of the day.
  • In obese patients or those not showing adequate response to Gliclazide 80 mg Tablets alone, additional therapy may be required.

Switching from another oral antidiabetic agent to Gliclazide 80 mg:
  • Gliclazide 80 mg can be used to replace other oral antidiabetic agents.
  • The dosage and the half-life of the previous antidiabetic agent should be taken into account when switching to Gliclazide 80 mg.
  • A transitional period is not generally necessary. A starting dose of 40-80 mg (½ to 1 tablet) should be used and this should be adjusted to suit the patient's blood glucose response, as described above.
  • When switching from a hypoglycaemic sulfonylurea with a prolonged half-life, a treatment free period of a few days may be necessary to avoid an additive effect of the two products, which might cause hypoglycaemia.

Combination treatment with other antidiabetic agents:
  • Gliclazide 80 mg can be given in combination with biguanides, alpha glucosidase inhibitors or insulin.
  • In patients not adequately controlled with Gliclazide 80 mg, concomitant insulin therapy can be initiated under close medical supervision.

Special Populations:
  • Elderly
  • Gliclazide 80 mg should be prescribed using the same dosing regimen recommended for patients under 65 years of age.
  • Renal impairment
  • In patients with mild to moderate renal insufficiency, the same dosing regimen can be used as in patients with normal renal function with careful patient monitoring. These data have been confirmed in clinical trials.
  • Patients at risk of hypoglycaemia
  • Undernourished or malnourished,
  • Severe or poorly compensated endocrine disorders (hypopituitarism, hypothyroidism, adrenocorticotrophic insufficiency),
  • Withdrawal of prolonged and/or high dose corticosteroid therapy,
  • Severe vascular disease (severe coronary heart disease, severe carotid impairment, diffuse vascular disease).
  • It is recommended that the minimum daily starting dose of 40-80 mg is used.
Request
Callback
Yes! I am Interested

Metformin Hcl & Glimepiride Tablets

Metformin Hcl & Glimepiride Tablets
  • Metformin Hcl & Glimepiride Tablets
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength501/502 mg
Packaging TypeBox
BrandFlomef-G
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionMetformin Hcl & Glimepiride Tablets

Indications:
  • It is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus who are already treated with a combination of glimepiride and metformin, given separately, or whose diabetes is not adequately controlled with metformin alone, or for those patients who have initially responded to glimepiride alone and require additional glycaemic control.

Dosage:

General
  • There is no fixed dosage regimen for the management of hyperglycaemia in patients with type 2 diabetes with metformin, glimepiride or any other pharmacologic agent. Dosage should be individualized on the basis of both effectiveness and tolerance. The combination should be given once daily with meals and should be started at a low dose.

Starting Dose for Patients Inadequately Controlled on Metformin Monotherapy
  • Based on the usual starting dose of glimepiride (1–2 mg daily),  501mg or  502mg may be initiated once daily, and gradually titrated after assessing adequacy of therapeutic response.

Starting Dose for Patients Who Initially Responded to Glimepiride Monotherapy and Require Additional Glycaemic Control
  • Based on the usual starting doses of metformin extended release (500 mg once daily),  501mg or  502mg may be initiated once daily, and gradually titrated after assessing adequacy of therapeutic response.

Starting Dose for Patients Switching from Combination Therapy of Glimepiride plus Metformin as Separate Tablets
  • 501 or 502 may be initiated based on the dose of glimepiride and metformin already being taken.
  • In case of inadequate glycaemic control with the above-mentioned regimes, consider one tablet of metformin HCL and glimepiride tablet 501mg and 502mg.
Request
Callback
Yes! I am Interested

Metformin Sustained Release Tablets 500mg/1gm

Metformin Sustained Release Tablets 500mg/1gm
  • Metformin Sustained Release Tablets 500mg/1gm
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength500 mg/1 G
Packaging TypeBox
BrandFlomef-SR
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionMetformin Sustained Release Tablets

Indications:
  • Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:
  • At high risk for developing overt type 2 diabetes mellitus and still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months
  • Treatment with metformin SR must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.
  • Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.
  • IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose
  • Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Metformin SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Dosage:
  • 2 tablets per day.
  • Reduction in the risk or delay of the onset of type 2 diabetes
  • Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycaemic control.
  • The therapy should be initiated with one tablet 500 mg once daily with the evening meal.
  • After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1C values to be within the normal range). A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets (2000 mg) once daily with the evening meal.
  • It is recommended to regularly monitor (every 3-6 months) the glycaemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.
  • A decision to re-evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.
  • Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:
  • The usual starting dose is one tablet of 500 mg once daily.
  • After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose is 4 tablets daily.
  • Dosage increases should be made in increments of 500mg every 10-15 days, up to a maximum of 2000mg once daily with the evening meal. If glycaemic control is not achieved on 2000mg once daily, 1000mg twice daily should be considered, with both doses being given with food. If glycaemic control is still not achieved, patients may be switched to standard metformin tablets to a maximum dose of 3000 mg daily.
  • In patients already treated with metformin tablets, the starting dose of should be equivalent to the daily dose of metformin immediate release tablets. In patients treated with metformin at a dose above 2000 mg daily, switching to is not recommended.
  • If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate at the dose indicated above.
  • metformin SR 750 mg and 1000 mg are intended for patients who are already treated with metformin tablets (prolonged or immediate release).
  • The dose of 750 mg or metforminSR 1000 mg should be equivalent to the daily dose of metformin tablets (prolonged or immediate release), up to a maximum dose of 1500 mg or 2000 mg respectively, given with the evening meal.
Request
Callback
Yes! I am Interested

Metformin Tablets 500mg/ 850mg/ 1000mg

Metformin Tablets 500mg/ 850mg/ 1000mg
  • Metformin Tablets 500mg/ 850mg/ 1000mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength500mg/850mg/1000mg
Packaging TypeBox
BrandFlomef
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionMetformin Tablets

Indications:
  • Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
  • Glucient SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.
  • In adults, Metformin film-coated tablets may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin.
  • In children from 10 years of age and adolescents, Metformin hydrochloride film-coated tablets may be used as monotherapy or in combination with insulin.
  • A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin hydrochloride as first-line therapy after diet failure

Dosage:
  • 2 tablets per day.

Monotherapy and combination with other oral antidiabetic agents:
  • - The usual starting dose is 500mg or 850mg metformin hydrochloride 2 or 3 times daily given during or after meals.
  • After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increase of dose may improve gastrointestinal tolerability.
  • The maximum recommended dose of metformin hydrochloride is 3 g daily, taken as 3 divided doses.
  • If transfer from another oral antidiabetic agent is intended: discontinue the other agent and initiate metformin hydrochloride at the dose indicated above.

Combination with insulin:
  • Metformin hydrochloride and insulin may be used in combination therapy to achieve better blood glucose control. Metformin hydrochloride is given at the usual starting dose of 500mg or 850mg metformin hydrochloride 2or3 times daily, while insulin dosage is adjusted on the basis of blood glucose measurements.
Request
Callback
Yes! I am Interested

Metformin, Glimepiride & Pioglitazone Tablets 517mg

Metformin, Glimepiride & Pioglitazone Tablets 517mg
  • Metformin, Glimepiride & Pioglitazone Tablets 517mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength517 mg
Packaging TypeBox
BrandMetpil-G
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionMetformin, Glimepiride & Pioglitazone Tablets

Indications:
  • Tablets are indicated once daily, as an adjunct to diet and exercise, to lower blood glucose. It is indicated as second-line therapy when diet, exercise, and the single agents or dual therapy do not result in adequate glycemic control in patients with type-2 diabetes.

Dosage:
  • Dosage should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose [which is for glimepiride=8mg; pioglitazone=45mg; metformin sustained-release=2000 mg]. The combination should be given once daily with meals and should be started at a low dose. The initial recommended dose is one tablet once daily. Dosage should not exceed 3 tablets per day.
Request
Callback
Yes! I am Interested

Saxagliptin Tablets 5mg/10mg

Saxagliptin Tablets 5mg/10mg
  • Saxagliptin Tablets 5mg/10mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
BrandSaxaflo
Dose5mg/10mg
UseClinical, Hospital Personal
Packaging Size2x14 tablets
CompositionSaxagliptin Tablets

Indications:
  • In patients inadequately controlled on their maximally tolerated dose of metformin alone
  • In combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products
  • In patients already being treated with the combination of saxagliptin and metformin as separate tablets.
  • Not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.

Monotherapy and Combination Therapy:
  • Is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage:
  • Saxagliptin 5 mg, dosed as 2.5 mg twice daily, plus the dose of metformin already being taken.

Recommended Dosage:
  • The recommended dosage of 2.5 mg or 5 mg once daily taken regardless of meals. tablets must not be split or cut.
Request
Callback
Yes! I am Interested

Voglibose Tablets 0.2mg/0.3mg

Voglibose Tablets 0.2mg/0.3mg
  • Voglibose Tablets 0.2mg/0.3mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength0.2mg/0.3mg
Packaging TypeBox
BrandVogbit-F
UsageClinical, Hospital, Personal
Packaging Size1x10 tablets
CompositionVoglibose Tablets

Indications:
  • For the treatment of diabetes.
  • It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
  • This medication is an alpha-glucosidase inhibitor, prescribed for diabetes mellitus.

Dosage:
  • The recommended dose is 200-300 mcg 3times/day.
Request
Callback
Yes! I am Interested
X

Explore more products



Reach Us
Reshma Mishra (CEO)
5/71, Rajeev Gali, Dayal Pur
Delhi -110094,India



Call Us

Share Us

F GT L


Send E-mailSend SMS